Intravacc sales process update

On May 3, 2023 the Ministry of Health, Welfare, and Sport (VWS) announced the sale of Intravacc B.V. and on December 28, 2023 VWS reached a proposed decision with FDI (First Dutch Innovations) regarding the sale of 100 percent of the shares of Intravacc B.V. In the coming months, both parties, in collaboration with Intravacc B.V., will work together to fulfill all the conditions necessary for the final transaction. Intravacc B.V. has been a State-Holding company since 2021, focusing on translational research and commercial contracted vaccine development for non-profit and for profit organizations. FDI is a part of First Dutch, the business group of the Rotterdam entrepreneur Peter Goedvolk, originating from the acquisition of TNO's commercial businesses. FDI invests in companies in the healthcare, climate, and energy sectors.

For customers and suppliers it will be business as usual and post-closing of the transaction Intravacc will continue its operations as a CDMO in the field of infectious disease and therapeutic vaccines.

If you have any questions, please feel free to contact us.


Kind Regards,

Jan Groen & Nathalie Laarakker
Board of Directors Intravacc B.V.